Escherichia coli O157:H7 infections:: Discordance between filterable fecal Shiga toxin and disease outcome

被引:49
作者
Cornick, NA
Jelacic, S
Ciol, MA
Tarr, PI
机构
[1] Univ Washington, Childrens Hosp & Reg Med Ctr, Div Gastroenterol, Seattle, WA 98105 USA
[2] Univ Washington, Childrens Hosp & Reg Med Ctr, Dept Pediat, Seattle, WA 98105 USA
[3] Univ Washington, Childrens Hosp & Reg Med Ctr, Dept Microbiol, Seattle, WA 98105 USA
[4] Iowa State Univ, Dept Vet Microbiol & Prevent Med, Ames, IA USA
关键词
D O I
10.1086/341295
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Shiga toxin (Stx)-producing Escherichia coli O157: H7 are the most common cause of hemolytic uremic syndrome (HUS). We detected free fecal Stx in 48%, 40%, and 17% of infected children with uncomplicated diarrhea, children who subsequently developed HUS, and children with HUS, respectively. Vero cell assay detected Stx more frequently than did a commercial Stx enzyme immunoassay. In children's stool samples obtained on or before day 4 of illness, each 10-fold decrease in titer was, paradoxically, associated with 3.8-fold increased odds of developing HUS (P = .03; 95% confidence interval, 0.77-19.7). The fecal Stx type did not correlate with the Stx expressed by bacteria grown in vitro and was not related to bacterial titer in the studied samples. These data suggest that therapeutic and diagnostic strategies directed toward binding or identifying intraintestinal fecal Stx may have limited success.
引用
收藏
页码:57 / 63
页数:7
相关论文
共 29 条
[1]  
Allerberger F, 2000, WIEN KLIN WOCHENSCHR, V112, P846
[2]   A PHASE-I STUDY OF CHEMICALLY SYNTHESIZED VEROTOXIN (SHIGA-LIKE TOXIN) PK-TRISACCHARIDE RECEPTORS ATTACHED TO CHROMOSORB FOR PREVENTING HEMOLYTIC-UREMIC SYNDROME [J].
ARMSTRONG, GD ;
ROWE, PC ;
GOODYER, P ;
ORRBINE, E ;
KLASSEN, TP ;
WELLS, G ;
MACKENZIE, A ;
LIOR, H ;
BLANCHARD, C ;
AUCLAIR, F ;
THOMPSON, B ;
RAFTER, DJ ;
MCLAINE, PN .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (04) :1042-1045
[3]  
ARMSTRONG GD, 1998, ESCHERICHIA COLI O15, P374
[4]   Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome [J].
Chandler, WL ;
Jelacic, S ;
Boster, DR ;
Ciol, MA ;
Williams, GD ;
Watkins, SL ;
Igarashi, T ;
Tarr, PI .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (01) :23-32
[5]   Shiga toxin-producing Escherichia coli infection:: Temporal and quantitative relationships among colonization, toxin production, and systemic disease [J].
Cornick, NA ;
Matise, I ;
Samuel, JE ;
Bosworth, BT ;
Moon, HW .
JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (01) :242-251
[6]   QUANTITATIVE MICROTITER CYTO-TOXICITY ASSAY FOR SHIGELLA TOXIN [J].
GENTRY, MK ;
DALRYMPLE, JM .
JOURNAL OF CLINICAL MICROBIOLOGY, 1980, 12 (03) :361-366
[7]   AN ENZYMATIC MUTANT OF SHIGA-LIKE TOXIN-II VARIANT IS A VACCINE CANDIDATE FOR EDEMA DISEASE OF SWINE [J].
GORDON, VM ;
WHIPP, SC ;
MOON, HW ;
OBRIEN, AD ;
SAMUEL, JE .
INFECTION AND IMMUNITY, 1992, 60 (02) :485-490
[8]   ESCHERICHIA-COLI O157-H7-ASSOCIATED COLITIS - A CLINICAL AND HISTOLOGICAL STUDY OF 11 CASES [J].
GRIFFIN, PM ;
OLMSTEAD, LC ;
PETRAS, RE .
GASTROENTEROLOGY, 1990, 99 (01) :142-149
[9]  
JOHNSON WM, 1983, LANCET, V1, P76
[10]   EPEC delivers the goods [J].
Kaper, JB .
TRENDS IN MICROBIOLOGY, 1998, 6 (05) :169-172